Devgen Nets $40M in Private Stock Placement | GenomeWeb
NEW YORK (GenomeWeb News) — Devgen, a Belgian biotech research company, said today it has raised €31 million ($40.7 million) in a private stock placement with new institutional investors.
 
Devgen said it placed 1.5 million shares priced at €20.75 apiece, and will apply for the shares to be admitted on Euronext, which is a cross-border European exchange. The company said the transaction should close on Feb. 20.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.